FDA Greenlights Higher-Dose Wegovy 7.2 mg as Novo Nordisk Fights Back Against Zepbound Dominance The weight-loss drug wars just heated up. The U.S. Food and Drug Administration has approved Novo Nordisk’s higher-dose version of Wegovy — a 7.2-milligram injection — giving the blockbuster semaglutide shot a fresh edge against rival Eli Lilly’s Zepbound. Novo plans … Read more
Eli Lilly’s Obesity Pill Orforglipron Challenges Novo Nordisk’s Oral Wegovy in Weight-Loss Market Race August 24, 2025 The obesity drug market, projected to surpass $73 billion by 2034, is witnessing a fierce competition between pharmaceutical giants Eli Lilly and Novo Nordisk. Eli Lilly’s oral GLP-1 receptor agonist, orforglipron, is emerging as a significant rival to … Read more
Eli Lilly’s $5 Billion Bet on Virginia: A Game-Changer for U.S. Drug Manufacturing In a bold move to fortify America’s pharmaceutical backbone amid looming trade tensions and surging demand for cutting-edge therapies, Eli Lilly and Company announced plans on September 16, 2025, to invest $5 billion in a state-of-the-art manufacturing facility in Goochland County, Virginia—just … Read more